Logo
x

Search

Subscribe Now

Lexicon

Lexicon’s Inpefa (sotagliflozin) Receives the US FDA’s Approval for the Treatment of Heart Failure

Lexicon’s Inpefa (sotagliflozin) Receives the US FDA’s Approval for the Treatment of Heart Failure

  • May 26, 2023
Lexicon Reports the US FDA’s Acceptance of NDA for Sotagliflozin to Treat Heart Failure

Lexicon Reports the US FDA’s Acceptance of NDA for Sotagliflozin to Treat Heart Failure

  • July 28, 2022
Lexicon Reports Submission of NDA to the US FDA for Sotagliflozin to Treat Heart Failure in Adults with Type 2 Diabetes

Lexicon Reports Submission of NDA to the US FDA for Sotagliflozin to Treat Heart Failure in Adults with Type 2 Diabetes

  • December 31, 2021
Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

  • January 3, 2020
Sanofi and Lexicon's Zynquista (sotagliflozin) Receive EU's MAA to Treat Type-1 Diabetes in Adults

Sanofi and Lexicon's Zynquista (sotagliflozin) Receive EU's MAA to Treat Type-1 Diabetes in Adults

  • April 29, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.